The challenge: Making AI in healthcare safe and clinically useful
BlueBridge Technologies is an Irish MedTech company working at the intersection of artificial intelligence, medical-device engineering and regulated healthcare.
Our focus is increasingly on one of the major challenges facing healthcare AI: moving from a technically impressive model to a safe, clinically useful medical product. The same underlying AI can carry very different clinical risks depending on how it is used, what decisions it informs, and the engineering, evidence and controls around it.
BlueBridge brings together AI capability with medical-device engineering, clinical evidence and regulatory expertise to address that wider system.
AI adoption: From Ireland to global AI programmes
BlueBridge is applying Irish medical-device expertise to emerging generations of AI-enabled healthcare products, working with companies, clinicians, universities and research teams in Ireland, Europe and North America. These projects include diagnostic tools for sepsis, at-home testing for low white blood cell counts, computer-vision systems that segment cardiac CT images, and continuous glucose monitoring augmented with additional health data for diabetes diagnosis and management.
Our work ranges from computer-vision software that segments cardiac CT scans to help clinicians plan heart-valve procedures, to patient-facing AI designed to support more of a person’s care. Programmes such as ADVOCATE envisage AI helping patients manage cardiovascular disease day to day, while involving clinicians when medical judgement is needed.
BlueBridge has worked in multidisciplinary teams involving organisations such as UCLA, University of Washington, and the University of Michigan in pursuing major US ARPA-H programmes. These include ADVOCATE, focused on patient-facing AI for cardiovascular care, and HEARING, focused on AI-enabled neurotechnology for hearing loss.
This gives an Irish SME a direct role in some of the most ambitious healthcare technology programmes where AI, medical-device development, and regulatory science converge.
Benefit of using AI to transform medtech development
BlueBridge is also adopting AI internally. Large language models and related technologies are being incorporated into activities including research, software development, regulatory evidence generation, requirements engineering, risk management, documentation and business intelligence.
Rather than treating AI simply as another productivity tool, we are exploring how AI-native development processes can reduce the cost and time required to bring regulated medical technologies to market while maintaining the standards of safety and efficacy required in healthcare.
This creates a second layer of innovation: AI within the medical product, and AI transforming the process used to create the medical product.
AI innovation: Bridging worlds
BlueBridge works with Irish innovators and academic groups to help translate early-stage technology and research into viable medical products.
Most current AI medical devices are radiology tools, and so radiology shows the scale of the opportunity. A large Swedish trial showed that these tools improved cancer detection and reduced workload. The opportunity is to achieve similar gains in cardiology, oncology, and other areas of diagnosis and care.
Ireland has deep expertise in medical-device engineering, clinical research, quality and regulation. We have an opportunity to build on that foundation: combining Ireland's established MedTech ecosystem with new capabilities in machine learning, software and generative AI.
An Irish capability with European relevance
Healthcare illustrates both Europe's opportunity and its challenge with AI.
Europe possesses deep clinical, scientific, engineering and regulated product development. The opportunity is not to build the largest model, but to combine those strengths with AI to create products that are safe, trusted, clinically useful, and commercially deployable.
That also means getting the regulatory environment right. AI-enabled medical devices can sit under both medical-device regulation and the EU AI Act, so clearer, more harmonised approval pathways will be important if Europe is to maintain strong patient protections while enabling innovation.
BlueBridge represents one example of how specialist capability developed in Ireland can contribute to that ambition: supporting Irish innovation at home while exporting AI-enabled MedTech expertise into international programmes and markets.